Novo Nordisk Seeks to Outbid Pfizer for Metsera - New York Business Journal

Pfizer sues to stop rival bid for drugmaker Metsera by Denmark’s Novo Nordisk

Pfizer is suing over in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday. Novo said it planned to buy Metsera in a deal that could be worth up to $9 billion, and Metsera said the offer appeared to be superior to Pfizer’s bid, which was . Metsera Inc. has no prod…

Exclusive: Pfizer mulls suing Metsera, Novo over topping bid

The NewsPfizer is muscling up in the slimdown fight. The company is preparing to sue Metsera and possibly Novo Nordisk after the Danish drugmaker behind Ozempic topped Pfizer’s bid for Metsera, a person familiar with the matter said. Pfizer said Novo’s bid — a richly priced but complicated two-step deal that Metsera’s board had previously rejected as too risky — skirts regulatory approvals and doesn’t qualify as “superior” to Pfizer’s agreed $7 …

Novo Nordisk seeks to outbid Pfizer for Metsera - New York Business Journal

Novo tops Pfizer with $6.5B bid for Metsera

The offer sparked a bidding war between the two large pharmas over the obesity drug specialist, with Pfizer alleging Novo’s offer is “illusory” and “structured in a way to circumvent antitrust laws.”

Novo Nordisk Challenges Pfizer with $6.5B Bid for Metsera

Novo Nordisk has thrown the obesity drug market into turmoil by making a $6.5 billion counteroffer to acquire Metsera, surpassing Pfizer’s previously announced $4.9 billion deal, which had appeared final after Metsera’s board unanimously approved it. Novo’s unsolicited bid also includes $2.5 billion in milestone payments, making the total package worth up to $9 billion. Metsera has labeled Novo’s offer as superior, giving Pfizer four days to pre…

Will Novo’s Metsera bid test the Trump administration's antitrust approach?

Novo Nordisk’s surprise $9 billion offer for obesity drugmaker Metsera could be the first major test of how the Trump administration’s FTC grapples with complex pharmaceutical mergers. The bid looks to pit ...